Toronto Dominion Bank Has $6.52 Million Stock Position in Revvity, Inc. (NYSE:RVTY)

Toronto Dominion Bank increased its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 40.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,374 shares of the company's stock after acquiring an additional 16,881 shares during the quarter. Toronto Dominion Bank's holdings in Revvity were worth $6,515,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RVTY. Nomura Holdings Inc. acquired a new position in shares of Revvity during the fourth quarter valued at approximately $447,000. Victory Capital Management Inc. lifted its holdings in shares of Revvity by 17.4% in the fourth quarter. Victory Capital Management Inc. now owns 70,250 shares of the company's stock valued at $7,841,000 after buying an additional 10,390 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Revvity by 41.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,072 shares of the company's stock valued at $1,352,000 after buying an additional 3,542 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Revvity by 87.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company's stock worth $881,000 after acquiring an additional 3,672 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in Revvity by 2.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 306,537 shares of the company's stock worth $34,213,000 after acquiring an additional 6,814 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Performance

Shares of NYSE:RVTY traded up $1.72 during midday trading on Tuesday, hitting $91.04. The company's stock had a trading volume of 927,607 shares, compared to its average volume of 952,783. Revvity, Inc. has a fifty-two week low of $87.70 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of 41.19, a PEG ratio of 3.82 and a beta of 1.02. The stock's 50 day simple moving average is $94.33 and its 200 day simple moving average is $107.84.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.98 earnings per share. As a group, research analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.31%. The ex-dividend date is Friday, July 18th. Revvity's dividend payout ratio (DPR) is presently 11.91%.

Analyst Ratings Changes

RVTY has been the topic of a number of recent research reports. The Goldman Sachs Group cut their target price on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Robert W. Baird cut their price objective on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a report on Tuesday, April 29th. Barclays decreased their target price on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company dropped their target price on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Revvity currently has a consensus rating of "Moderate Buy" and an average target price of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.